All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @becominglashonda on TikTok · 15s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @becominglashonda's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Y'all I found a media in my GLP1 journey where I don't care to eat
  2. 0:06It's been two days now and all I had was a protein shake and peanut butter
  3. 0:14No interest

@becominglashonda's GLP-1 appetite claims, fact-checked

BecomingLashonda

TikTok creator

14.8K viewsWatch on TikTok

Quick answer

The creator describes two days of near-total appetite suppression on tirzepatide, consuming only a protein shake and peanut butter, and frames this as a positive outcome. This level of caloric restriction on a GLP-1 receptor agonist raises legitimate concerns about lean muscle preservation, micronutrient intake, and whether the dose is appropriately titrated for her tolerance. Clinical management of GLP-1 therapy includes monitoring for excessive appetite suppression, which can contribute to muscle loss and nutritional deficiency if not actively countered with intentional eating and adequate protein intake.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @becominglashonda's GLP-1 appetite claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@becominglashonda's GLP-1 appetite claims, fact-checked" from BecomingLashonda. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator describes two days of near-total appetite suppression on tirzepatide, consuming only a protein shake and peanut butter, and frames this as a positive outcome.

The reason this review is not generic is the source wording and the canonical claim label "glp1 when you finally hit that point in your glp 1 journey where." In this clip, the useful excerpt is: "Y'all I found a media in my GLP1 journey where I don't care to eat It's been two days now and all I had was a protein shake and peanut butter No interest" That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Two days of near-zero food intake on a GLP-1 medication is a clinical warning sign, not a milestone.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator describes two days of near-total appetite suppression on tirzepatide, consuming only a protein shake and peanut butter, and frames this as a positive outcome.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator describes two days of near-total appetite suppression on tirzepatide, consuming only a protein shake and peanut butter, and frames this as a positive outcome. This level of caloric restriction on a GLP-1 receptor agonist raises legitimate concerns about lean muscle preservation, micronutrient intake, and whether the dose is appropriately titrated for her tolerance. Clinical management of GLP-1 therapy includes monitoring for excessive appetite suppression, which can contribute to muscle loss and nutritional deficiency if not actively countered with intentional eating and adequate protein intake.
  • Tirzepatide's appetite suppression is real and documented in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), but extreme suppression is a side effect to manage, not a target outcome.
  • Two days of near-zero food intake on a GLP-1 medication is a clinical warning sign, not a milestone. Contact your prescriber if this happens.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • Tirzepatide's appetite suppression is real and documented in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), but extreme suppression is a side effect to manage, not a target outcome.
  • Two days of near-zero food intake on a GLP-1 medication is a clinical warning sign, not a milestone. Contact your prescriber if this happens.
  • Obesity Medicine Association guidelines recommend at least 1.2g of protein per kilogram of body weight daily during GLP-1-assisted weight loss to protect muscle mass.
  • Blum et al. (2021, Obesity) confirmed that GLP-1 medications reduce food cue reactivity and food noise, validating the general experience she describes, but that is different from barely eating for two days.
  • Cava et al. (2017, Nutrients) found that inadequate protein during caloric restriction accelerates muscle catabolism, which is a direct risk when appetite suppression goes unmanaged.
  • If a GLP-1 medication is suppressing your appetite to the point where you cannot meet basic nutritional needs, dose adjustment or titration modification is a medically appropriate option worth discussing with your prescriber.
  • Social media posts framing extreme restriction as success can set a harmful template for other GLP-1 users who may interpret it as the intended goal of treatment.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @becominglashonda actually say?

She described finding a point in her GLP-1 journey where she has "no interest" in eating. Over two days, she consumed only a protein shake and peanut butter. She framed this as a positive milestone, a place where she "don't care to eat." That framing is worth examining carefully, because there's a meaningful difference between reduced appetite and near-total food aversion.

To be fair, she's describing a real, documented effect of GLP-1 receptor agonists like tirzepatide. These medications do suppress appetite, sometimes dramatically. But two days of minimal intake isn't a badge of honor. It's a clinical signal that deserves attention, not celebration on social media.

Does the science back this up?

Yes and no. Appetite suppression is real and well-documented, but the degree she's describing crosses into a risk zone that the trials flagged repeatedly.

Tirzepatide works on both GIP and GLP-1 receptors, which gives it a stronger appetite-suppressing effect than semaglutide alone. In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), participants on tirzepatide lost significant weight, but the trial also tracked adverse events carefully. Nausea, vomiting, and reduced appetite were among the most common side effects, and they were dose-dependent. Critically, the trial protocol included dietary counseling specifically because inadequate nutrition is a real risk on these medications.

When appetite suppression becomes severe enough that someone eats almost nothing for two days, you're looking at potential muscle loss, micronutrient deficiency, and in some cases, dangerous caloric restriction that can stress the heart and other organs. A protein shake and peanut butter is not a nutritional plan. It's what happens when the medication is doing more than the person is managing.

What did they get wrong (or right)?

She got the basic phenomenon right. GLP-1 and dual GIP/GLP-1 agonists do reduce food noise and appetite. That part is accurate and well-supported. Some patients do describe a shift where eating feels functional rather than emotional, and researchers have studied this. Blum et al. (2021, Obesity) found that semaglutide reduced food cue reactivity and what patients described as intrusive food thoughts. That experience is real.

What she got wrong is the framing. Presenting near-zero food intake over 48 hours as a milestone rather than a warning sign is the problem. Adequate protein intake is especially important on GLP-1 medications because rapid weight loss increases the risk of losing lean muscle mass. Cava et al. (2017, Nutrients) reviewed how very low calorie intake during weight loss accelerates muscle catabolism without sufficient protein. A single protein shake does not clear that bar.

There's also no mention of hydration, electrolytes, or whether she's spoken to a prescriber about this level of suppression. That absence matters.

What should you actually know?

If you're on a GLP-1 medication and find yourself going 48 hours on minimal food, that is not the goal. It is a side effect that needs to be managed, and in some cases, it's a reason to contact your prescriber about adjusting your dose.

Clinical guidelines from the Obesity Medicine Association recommend that patients on GLP-1 medications prioritize protein intake of at least 1.2 grams per kilogram of body weight to preserve lean mass during weight loss. "Eating because you need to, not because you want to" is only healthy if you are actually eating enough to meet your needs.

Here's what the evidence supports as appropriate:

  • Reduced appetite is expected and can be a useful therapeutic effect
  • Complete food aversion lasting more than a day is a side effect, not a feature
  • Protein and hydration goals still apply, even when you're not hungry
  • Dose titration exists partly to manage this, if suppression is too severe, your prescriber can adjust
  • Social media framing of extreme restriction as success can cause real harm to people who take it as a template

The medication is doing something real. Managing it responsibly is the actual work.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

BecomingLashonda · TikTok creator

14.8K views on this video

When you finally hit that point in your GLP-1 journey where you eat because you need to, not because you want to!! #glp1community #glp #tirzepatide #food #control #becominglashonda #weightloss #health

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tirzepatide's appetite suppression?

Tirzepatide's appetite suppression is real and documented in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), but extreme suppression is a side effect to manage, not a target outcome.

What does the video say about two days of near-zero food intake on a glp-1 medication?

Two days of near-zero food intake on a GLP-1 medication is a clinical warning sign, not a milestone. Contact your prescriber if this happens.

What does the video say about obesity medicine association guidelines recommend at least 1.2g of protein?

Obesity Medicine Association guidelines recommend at least 1.2g of protein per kilogram of body weight daily during GLP-1-assisted weight loss to protect muscle mass.

What does the video say about blum et al. (2021, obesity) confirmed?

Blum et al. (2021, Obesity) confirmed that GLP-1 medications reduce food cue reactivity and food noise, validating the general experience she describes, but that is different from barely eating for two days.

What does the video say about cava et al. (2017, nutrients) found?

Cava et al. (2017, Nutrients) found that inadequate protein during caloric restriction accelerates muscle catabolism, which is a direct risk when appetite suppression goes unmanaged.

What does the video say about if a glp-1 medication?

If a GLP-1 medication is suppressing your appetite to the point where you cannot meet basic nutritional needs, dose adjustment or titration modification is a medically appropriate option worth discussing with your prescriber.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by BecomingLashonda, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.